Cited by 75Viral Infectious Diseases and Gene Expression in InsectsFluid Dynamics and MixingVirus-based gene therapy research

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.

Development of suspension adapted Vero cell culture process technology for production of viral vaccines

Open access

Abstract

Vero cells are considered as the most widely accepted continuous cell line by the regulatory authorities (such as WHO) for the manufacture of viral vaccines for human use. The growth of Vero cells is anchorage-dependent. Scale-up and manufacturing in adherent cultures are labor intensive and complicated. Adaptation of Vero cells to grow in suspension will simplify subcultivation and process scale-up significantly, and therefore reduce the production cost. Here we report on a successful adaptation of adherent Vero cells to grow in suspension in a serum-free and animal component-free medium (IHM03) developed in-house. The suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as what was observed for the adherent Vero cells grown in commercial serum-free media and with a cell doubling time of 40–44 h. Much higher cell density (8 × 106 cells/mL) was achieved in a batch culture when three volume of the culture medium was replaced during the batch culture process. Both adherent and suspension Vero cells from various stages were tested for their authenticity using short tandem repeat analysis. Testing result indicates that all Vero cell samples had 100% concordance with the Vero DNA control sample, indicating the suspension cells maintained their genetic stability. Furthermore, suspension Vero cells at a passage number of 163 were assayed for tumorigenicity, and were not found to be tumorigenic. The viral productivity of suspension Vero cells was evaluated by using vesicular stomatitis virus (VSV) as a model. The suspension cell culture showed a better productivity of VSV than the adherent Vero cell culture. In addition, the suspension culture could be infected at higher cell densities, thus improving the volumetric virus productivity. More than one log of increase in the VSV productivity was achieved in a 3L bioreactor perfusion culture infected at a cell density of 6.8 × 106 cells/mL.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

Adherent Vero cells were successfully adapted to serum-free, animal component-free suspension culture in in-house IHM03 medium, retaining genetic stability and non-tumorigenicity. The suspension process improved VSV productivity, especially when infected at high cell density in perfusion bioreactor culture.

Key findings

  • Suspension-adapted Vero cells grew in IHM03 with a doubling time of 40–44 h; adaptation succeeded only in IHM03, while commercial serum-free media led to aggregation and failed adaptation.
  • Batch shake-flask cultures reached slightly above 2 × 10^6 cells/mL; replacing medium three times during batch culture increased viable cell density to 8 × 10^6 cells/mL.
  • STR analysis showed 100% concordance with the Vero DNA control for adherent and suspension cells at various passages, and suspension Vero cells at passage 163 were not tumorigenic in nude mice.
  • VSV productivity was higher in suspension than adherent Vero cultures; increasing infection density from 0.87 × 10^6 to 2.5 × 10^6 cells/mL raised volumetric productivity from 2.3 × 10^9 to 8.9 × 10^9 TCID50%/mL (3.8-fold), and a 3 L perfusion culture infected at 6.8 × 10^6 cells/mL achieved more than one log higher VSV productivity than 1 × 10^6 cells/mL controls.

Methods

  • Adherent Vero cells (ATCC CCL-81) were adapted to suspension in serum-free IHM03 by serial passaging in shake flasks; growth was evaluated in batch, fed-batch, and medium-replacement cultures, then scaled to a controlled 3.5 L bioreactor in batch and perfusion modes.
  • Authentication used short tandem repeat (STR) analysis; tumorigenicity was tested by subcutaneous injection of 10^7 suspension Vero cells at passage 163 into nude mice, with positive and negative controls.
  • Viral productivity was assessed using recombinant VSV-GFP at MOI 0.1; supernatant titers were measured by TCID50%/mL on HEK293A cells using the Spearman-Karber method.

Limitations

  • The paper states that further increasing infection density to 5.0 × 10^6 cells/mL did not improve VSV production, indicating potential nutrient limitation, and that the process needs optimization to avoid nutrient and other limitations.
  • The paper notes the suspension-adapted cells had a longer doubling time (40–44 h) than actively growing adherent Vero cultures (~24 h), likely due partly to serum removal and shear stress.
  • Evident from the text: viral productivity was evaluated only with VSV-GFP as a model, and tumorigenicity was tested at a single passage number (163), so broader vaccine virus and long-term safety conclusions are not established here.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2019.07.003

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 14 cited sources checked · 0 supported · 0 flagged

  • Findingown data

    Suspension adapted Vero cell cultures in IHM03 had a cell doubling time of 40-44 h.

    “The suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as what was observed for the adherent Vero cells grown in commercial serum-free media and with a cell doubling time of 40-44 h.”
    • Also stated in: § 3.1. Adaptation of adherent Vero cells to grow in suspension in serumfree media · plain
      “The Vero cells started to grow in suspension only in serum-free IHM03 medium after 5-8 weeks of adaptation process to reach a doubling time in a range between 40 and 44 h.”
    Quote in the paperSubstantial claim
  • Findingown data

    All Vero cell samples tested, including adherent and suspension adapted cells at various passages, had 100% concordance with the Vero DNA control sample in STR analysis.

    “Testing result indicates that all Vero cell samples had 100% concordance with the Vero DNA control sample, indicating the suspension cells maintained their genetic stability.”
    • Also stated in: § 3.3. Genetic stability of adherent and suspension adapted Vero cells over the culture passaging and maintenance process · hedged
      “Electropherogram results of all samples showed 100% concordance with the Vero DNA control sample, indicating that the adherent and suspension adapted Vero cells retained their genetic stability after passaging and/or adapting to grow in suspension in serumfree IHM03 medium for many passages.”
    Quote in the paperSubstantial claim
  • Findingown data

    Suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as adherent Vero cells grown in commercial serum-free media.

    “The suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as what was observed for the adherent Vero cells grown in commercial serum-free media”
    Quote in the paperSubstantial claim
  • Findingown data

    Much higher cell density (8 × 10^6 cells/mL) was achieved in a batch culture when three volumes of culture medium were replaced during the batch culture process.

    “Much higher cell density (8 Â 10 6 cells/mL) was achieved in a batch culture when three volume of the culture medium was replaced during the batch culture process.”
    • Also stated in: § 3.2. Growth of suspension adapted Vero cell in batch cultures · plain
      “The data in Fig. 2 showed the viable cell density in shake flask cultures reached 8 Â 10 6 cells/mL after 3 complete medium replacements during the batch culture process.”
    Quote in the paperSubstantial claim
  • Findingown data

    Suspension adapted Vero cells at passage number 163 were not found to be tumorigenic under the conditions of the study.

    “Furthermore, suspension Vero cells at a passage number of 163 were assayed for tumorigenicity, and were not found to be tumorigenic.”
    • Also stated in: § 3.4. Tumorigenicity of suspension adapted Vero cells · plain
      “In conclusion, under the conditions of this study, the test article, suspension adapted Vero cell at a passage number of 163, was not found to be tumorigenic.”
    Quote in the paperSubstantial claim
  • It may state two separate claims as one. 12
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 3
  • It may state two separate claims as one.

    Findingown data

    Suspension culture could be infected at higher cell densities, improving volumetric virus productivity.

    “In addition, the suspension culture could be infected at higher cell densities, thus improving the volumetric virus productivity.”
    Quote in the paperSubstantial claim
  • It may state two separate claims as one.

    Findingown data

    Cell density increased by 2.2-2.5 × 10^6 cells/mL after perfusing each bioreactor volume of medium, roughly equivalent to the maximum cell density achieved in batch culture.

    “The cell density increased by 2.2-2.5 Â 10 6 cells/mL after perfusing each bioreactor volume of medium, which was roughly equivalent to the maximum cell density achieved in the batch culture.”
    Quote in the paperSubstantial claim
  • The quote only partly states this claim.

    Findingown data

    None of the mice receiving suspension adapted Vero cells at passage 163 or negative control had evidence of neoplastic cellular proliferation at the injection site or in other organs or tissues examined.

    “None of the mice receiving the test article (Group 1), or serum free cell culture media only (Group 3) had evidence of neoplastic cellular proliferation, i.e. tumors, at the injection site or in other organs or tissues examined.”
    Quote in the paperSubstantial claim
  • It may state two separate claims as one.

    Findingown data

    In commercial serum-free medium cultures, Vero cells aggregated and adaptation was not successful.

    “While in the commercial serum-free medium cultures, the Vero cells aggregated and the adaptation was not successful.”
    Quote in the paperSubstantial claim
  • It may state two separate claims as one.

    Findingown data

    Suspension Vero cells showed similar growth rate in 3L bioreactor as in small shake flask cultures, but with much less cell aggregates.

    “The suspension Vero cell showed a similar growth rate (data not shown) as those achieved in the small shake flask cultures, but with much less cell aggregates.”
    Quote in the paperSubstantial claim
  • It may state two separate claims as one.

    Findingown data

    Volumetric productivity of VSV peaked at 28 h post infection in the 3L bioreactor culture, while the highest titer of VSV appeared in the shake flask culture after 45 h post infection.

    “The volumetric productivity of VSV peaked at 28 h post infection in the 3L bioreactor culture, while the highest titer of VSV appeared in the shake flask culture after 45 h post infection.”
    Quote in the paperNot a substantial claim
  • It may state two separate claims as one.

    Findingown data

    Cell density reached 4.2 × 10^6 cells/mL after 2 days of perfusion at 0.5 VVD, and further increased to 6.8 × 10^6 cells/mL when the culture was operated at 1 VVD for one additional day before virus infection.

    “The cell density reached 4.2 Â 10 6 cells/mL after 2 days of perfusion at a rate of 0.5 VVD, and further increased to 6.8 Â 10 6 cells/mL when the culture was operated at a perfusion rate of 1 VVD for one additional day before the virus infection.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    Vero cells are considered the most widely accepted continuous cell line by regulatory authorities such as WHO for the manufacture of viral vaccines for human use.

    “Vero cells are considered as the most widely accepted continuous cell line by the regulatory authorities (such as WHO) for the manufacture of viral vaccines for human use.”
    • Also stated in: § 1. Introduction · plain
      “Vero cells are considered as the most widely accepted continuous cell line by the regulatory authorities (such as WHO) for the manufacture of viral vaccines for human use [10].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [10]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • It may state two separate claims as one.

    Interpretationreasoning

    Adaptation of Vero cells to grow in suspension will simplify subcultivation and process scale-up significantly, and therefore reduce production cost.

    “Adaptation of Vero cells to grow in suspension will simplify subcultivation and process scale-up significantly, and therefore reduce the production cost.”
    • Also stated in: § 1. Introduction · plain
      “Adaptation of Vero cells to grow in suspension will simplify handling of cultures such as inoculation, cell passaging and process scale-up significantly, and therefore, reduce the production cost.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Vero cells are anchorage-dependent and can only proliferate when provided with a suitable surface.
  • It may state two separate claims as one.

    Premisecitation

    Scale-up and manufacturing in adherent cultures are labor intensive and complicated.

    “Scale-up and manufacturing in adherent cultures are labor intensive and complicated.”
    • Also stated in: § 1. Introduction · plain
      “Scale-up of cell mass for large-scale adherent cell-based manufacturing is of particular concern or challenging as attachmentdependent culture processing generally requires more steps (the required detachment and reattachment of cells during passaging) and time than suspension [13].”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [13]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [16]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [22]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim.

    Study design and conductcitation

    STR analysis of Vero cell samples was performed according to the method developed by Almeida et al.

    “DNA samples were extracted from adherent and suspension adapted Vero cells at various passages and shipped to the National Institute of Standards and Technology (Gaithersburg, MD) for short tandem repeat (STR) analysis according to the method developed by Almeida et al. [1].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [1]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • It may state two separate claims as one.

    Interpretationown data

    The adapted cells could be used for high yield productions of viruses, such as VSV, at high cell density and in suspension cultures at reduced production cost.

    “These adapted cells could be used for high yield productions of viruses, such as VSV, in at high cell density and in suspension cultures at reduced production cost.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: VSV is a representative model for viral productivity of other vaccine viruses.
  • It may state two separate claims as one.

    Study design and conductown data

    Cell density in the perfusion bioreactor was verified by daily cell counts, and cell viability was always higher than 98%.

    “The cell density was verified by daily cell counts, and the cell viability was always higher than 98%.”
    Quote in the paperNot a substantial claim
  • It may state two separate claims as one.

    Interpretationown data

    Cell growth in the batch culture might not be limited by availability of nutrients or inhibited by the common metabolites lactate and ammonia.

    “These data indicate that the cell growth in the batch culture might not be limited by the availability of nutrients or inhibited by the common metabolites, lactate and ammonia.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Interpretationreasoning

    The slightly declined virus productivity in adherent culture could be due to increased confluence percentage of monolayer or availability of nutrients in the T-flask culture.

    “The slightly declined virus productivity could be due to increased confluence percentage of monolayer or availability of nutrients in the T-flask culture.”
    Quote in the paperNot a substantial claim
15 of 15
  • The paper relies on this without support.

    Vero cells are anchorage-dependent and can only proliferate when provided with a suitable surface.

    “The growth of Vero cells is anchorage-dependent.”
    “The growth of Vero cells is anchorage-dependent and Vero cells can only proliferate when provided with a suitable surface.”
  • The paper relies on this without support.

    VSV is a representative model for viral productivity of other vaccine viruses.

    “Recombinant vesicular stomatitis virus expressing the green fluorescent protein (VSV-GFP) [20], a generous gift of Dr. John Bell, Ottawa Hospital Research Institute, was selected as a model virus to evaluate the virus productivity of adherent and suspension adapted Vero cells.”
2 of 2

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Madeline, 2015, Culturing a duck es-derived cell line in single-use bioreactors: a rapid, efficient, and cost-effective vaccine manufacturing system based on suspension culture., Bioprocess Int, 13, 26
  2. Morrow KJ, Sha M. Vero Cell-based Vaccine Production: Rabies and Influenza Cell lines, Media and Bioreactor Options. Review Article. 2013. <https://online-shop.eppendorf.us/US-en/eshopdownload/downloadbykey/93796_186> [accessed 29.11.2018].

Cited by

Sorted by citations

Metadata

Authors
Shen, C. F., Guilbault, C., Li, X., Elahi, S. M., Ansorge, S., Kamen, A., & Gilbert, R.
Affiliations
  • National Research Council Canada (CA)
  • China National Biotechnology (China) (CN)
Corresponding author
Shen, Chun Fang
Venue
Vaccine
Publisher
Elsevier BV
Published
2019-11
Volume
37
Issue
47
Pages
6996-7002
ISSN
0264-410X (ISSN-L)
OpenAlex
W2953696603
Cited by
75
References
19
Citations by year
2026: 9 · 2025: 7 · 2024: 14 · 2023: 11 · 2022: 15 · 2021: 13 · 2020: 4 · 2019: 2
FWCI
2.43
Type
journal article
Language
en
Open access
Locations
  • Vaccine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
Funders
National Institute of Standards and Technology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Physical Sciences › Chemical Engineering › Fluid Flow and Transfer Processes › Fluid Dynamics and Mixing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
Vero cells, cell suspension culture, viral vaccine production, serum-free medium, cell line authentication, short tandem repeat profiling, vesicular stomatitis virus, perfusion bioreactor, adherent culture, process scale-up
MeSH terms
Animals, Cell Count, Cell Line, Chlorocebus aethiops, Culture Media, Vero Cells, Vesicular stomatitis Indiana virus, Viral Vaccines, Virus Cultivation, Culture Media, Serum-Free, Vesiculovirus, Bioreactors, Batch Cell Culture Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review